← Leaderboards
Quynh-Thu X Le
Stanford University
$15,492,013
Attributed
$21,419,948
Total exposure
16
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $20.7M · FY2006–25$25M$18.8M$12.5M$6.3M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$102,971,095 · 18
By mechanism
U10$77,518,765 · 3
P01$13,570,287 · 7
R01$11,072,531 · 5
R21$436,687 · 1
P30$369,825 · 1
R13$3,000 · 1
Top collaborators
- Robert S Mannel12 shared
- Norman Wolmark12 shared
- Steven Edward Coutre6 shared
- Branimir I Sikic6 shared
- Heather Ann Wakelee6 shared
- Albert Koong5 shared
- Nan Xiao5 shared
- Maximilian Diehn4 shared
Most similar at Stanford University
Same institution · by research overlap
- Nan Xiao$979,019
- Sandra J. Horning$4,271,994
- Branimir I Sikic$8,041,001
- Victor G Carrion$873,125
- Maximilian Diehn$12,346,945
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsRadiation TherapyRadiationTumorHead And Neck CancerCollaborationsPathway InteractionsCellsProgramsClinical TrialsCancer PatientHypoxiaMolecularMemberNeoplastic CellPrincipal InvestigatorSuccessDesignResearch PersonnelHead And Neck StructureFutureGrowthDosePharmaceutical Preparations
Grant awards (74)
NRG Oncology Network Group Operations Center$14,924,956
U10 · FY2025 · CA
Molecular Strategies to Widen the Therapeutic Index of Radiotherapy$1,990,934
P01 · FY2025 · CA · contact PI
Precision imaging for risk stratification and personalized therapy of oropharyngeal cancer$604,860
R01 · FY2025 · DE
The role of Galectin-1 in shaping the immune suppressive landscape in head and neck cancer$576,429
R01 · FY2025 · DE · contact PI
NRG Oncology Annual BIQSFP Progress Reports$400,777
U10 · FY2025 · CA
Administration Core$395,500
P01 · FY2025 · CA · contact PI
Project 2: ALDH3A1 Activation for Radioprotection of Salivary Glands and Other Head and Neck Epithelial Tissues$381,386
P01 · FY2025 · CA · contact PI
Radiation Biology$169,872
P30 · FY2025 · CA · contact PI
NRG Oncology Network Group Operations Center$13,566,633
U10 · FY2024 · CA
Molecular Strategies to Widen the Therapeutic Index of Radiotherapy$1,922,740
P01 · FY2024 · CA · contact PI
NRG Oncology Network Group Operations Center$1,106,894
U10 · FY2024 · CA
Precision imaging for risk stratification and personalized therapy of oropharyngeal cancer$591,021
R01 · FY2024 · DE
The role of Galectin-1 in shaping the immune suppressive landscape in head and neck cancer$564,874
R01 · FY2024 · DE · contact PI
Administration Core$375,785
P01 · FY2024 · CA · contact PI
Project 2: ALDH3A1 Activation for Radioprotection of Salivary Glands and Other Head and Neck Epithelial Tissues$372,910
P01 · FY2024 · CA · contact PI
Radiation Biology$66,651
P30 · FY2024 · CA · contact PI
NRG Oncology Network Group Operations Center$14,419,380
U10 · FY2023 · CA
Molecular Strategies to Widen the Therapeutic Index of Radiotherapy$2,021,847
P01 · FY2023 · CA · contact PI
NRG Oncology Network Group Operations Center$1,094,150
U10 · FY2023 · CA
NRG Oncology Network Group Operations Center - BIQSFP Progress Report & Carryover GY10$772,082
U10 · FY2023 · CA
Precision imaging for risk stratification and personalized therapy of oropharyngeal cancer$601,493
R01 · FY2023 · DE
The role of Galectin-1 in shaping the immune suppressive landscape in head and neck cancer$576,376
R01 · FY2023 · DE · contact PI
Project 2: ALDH3A1 Activation for Radioprotection of Salivary Glands and Other Head and Neck Epithelial Tissues$392,627
P01 · FY2023 · CA · contact PI
Administration Core$387,743
P01 · FY2023 · CA · contact PI
NRG Oncology Network Group Operations Center$322,489
U10 · FY2023 · CA
Radiation Biology$66,651
P30 · FY2023 · CA · contact PI
NRG Oncology Network Group Operations Center$11,772,013
U10 · FY2022 · CA
Molecular Strategies to Widen the Therapeutic Index of Radiotherapy$2,146,256
P01 · FY2022 · CA · contact PI
NRG Oncology Network Group Operations Center - GY9 BIQSFP Reports/Budgets$1,270,235
U10 · FY2022 · CA
Admin-Core-001$1,270,235
U10 · FY2022 · CA
Precision imaging for risk stratification and personalized therapy of oropharyngeal cancer$633,059
R01 · FY2022 · DE
The role of Galectin-1 in shaping the immune suppressive landscape in head and neck cancer$570,587
R01 · FY2022 · DE · contact PI
Project 2: ALDH3A1 Activation for Radioprotection of Salivary Glands and Other Head and Neck Epithelial Tissues$413,625
P01 · FY2022 · CA · contact PI
Administration Core$400,732
P01 · FY2022 · CA · contact PI
Radiation Biology$66,651
P30 · FY2022 · CA · contact PI
2022 Nasopharyngeal Carcinoma Gordon Research Conference$3,000
R13 · FY2022 · CA · contact PI
NRG Oncology Network Group Operations Center$13,819,761
U10 · FY2021 · CA
The role of Galectin-1 in shaping the immune suppressive landscape in head and neck cancer$574,961
R01 · FY2021 · DE · contact PI
Characterization and Targeting the GDNF and Other Pathways in Salivary Stem Cells$388,727
R01 · FY2019 · DE · contact PI
Stanford University NCTN- Network Lead Academic Site$518,824
U10 · FY2018 · CA
Characterization and Targeting the GDNF and Other Pathways in Salivary Stem Cells$388,674
R01 · FY2018 · DE · contact PI
Stanford University NCTN- Network Lead Academic Site$547,394
U10 · FY2017 · CA
Characterization and Targeting the GDNF and Other Pathways in Salivary Stem Cells$388,624
R01 · FY2017 · DE · contact PI
Novel Approaches to Mitigate Radiation-Induced Xerostomia in Head and Neck Cance$202,016
P01 · FY2017 · CA · contact PI
Stanford University NCTN- Network Lead Academic Site$490,000
U10 · FY2016 · CA
Characterization and Targeting the GDNF and Other Pathways in Salivary Stem Cells$390,075
R01 · FY2016 · DE · contact PI
Targeting Galectin-1 with radiation in lung cancer$326,986
R01 · FY2016 · CA · contact PI
Novel Approaches to Mitigate Radiation-Induced Xerostomia in Head and Neck Cance$202,016
P01 · FY2016 · CA · contact PI
Stanford University NCTN- Network Lead Academic Site$576,471
U10 · FY2015 · CA
Characterization and Targeting the GDNF and Other Pathways in Salivary Stem Cells$401,937
R01 · FY2015 · DE · contact PI
Targeting Galectin-1 with radiation in lung cancer$326,940
R01 · FY2015 · CA · contact PI
Novel Approaches to Mitigate Radiation-Induced Xerostomia in Head and Neck Cance$202,016
P01 · FY2015 · CA · contact PI
Stanford University NCTN- Network Lead Academic Site$70,000
U10 · FY2015 · CA
Stanford University NCTN- Network Lead Academic Site$576,471
U10 · FY2014 · CA
Targeting Galectin-1 with radiation in lung cancer$317,077
R01 · FY2014 · CA · contact PI
Novel Approaches to Mitigate Radiation-Induced Xerostomia in Head and Neck Cance$195,956
P01 · FY2014 · CA · contact PI
Targeting Galectin-1 with radiation in lung cancer$307,201
R01 · FY2013 · CA · contact PI
Novel Approaches to Mitigate Radiation-Induced Xerostomia in Head and Neck Cance$202,016
P01 · FY2013 · CA · contact PI
Targeting Galectin-1 with radiation in lung cancer$326,810
R01 · FY2012 · CA · contact PI
A Novel Therapy for Radiation-Induced Xerostomia Using Human Salivary Stem Cells$238,465
R21 · FY2012 · DE · contact PI
Osteopontin & Tumor Progression in Head and Neck Cancers$256,624
P01 · FY2011 · CA · contact PI
A Novel Therapy for Radiation-Induced Xerostomia Using Human Salivary Stem Cells$198,222
R21 · FY2011 · DE · contact PI
Defining Molecular Markers for Tumor Hypoxia$376,458
R01 · FY2010 · CA · contact PI
Osteopontin & Tumor Progression in Head and Neck Cancers$283,095
P01 · FY2010 · CA · contact PI
Defining Molecular Markers for Tumor Hypoxia$373,841
R01 · FY2009 · CA · contact PI
Defining Molecular Markers for Tumor Hypoxia$316,416
R01 · FY2009 · CA · contact PI
Osteopontin & Tumor Progression in Head and Neck Cancers$279,811
P01 · FY2009 · CA · contact PI
Defining Molecular Markers for Tumor Hypoxia$365,944
R01 · FY2008 · CA · contact PI
Osteopontin & Tumor Progression in Head and Neck Cancers$273,929
P01 · FY2008 · CA · contact PI
Defining Molecular Markers for Tumor Hypoxia$367,132
R01 · FY2007 · CA · contact PI
Osteopontin & Tumor Progression in Head and Neck Cancers$270,723
P01 · FY2007 · CA · contact PI
Defining Molecular Markers for Tumor Hypoxia$416,029
R01 · FY2006 · CA · contact PI
MARKERS FOR TUMOR HYPOXIA IN HEAD AND NECK CANCER$0
P01 · FY2002 · CA
MARKERS FOR TUMOR HYPOXIA IN HEAD AND NECK CANCER$0
P01 · FY2001 · CA